focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.295
Bid: 2.21
Ask: 2.38
Change: 0.00 (0.00%)
Spread: 0.17 (7.692%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2.295
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss

Mon, 25th Mar 2024 10:55

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 36% at 2.61 pence, 12-month range 0.82p-3.80p. The drug discovery and development company updates on Incanthera PLC's commercial skincare deal, announced in December 2023, with Marionnaud, part of the AS Watson Group. Says the first order from Marionnaud has now doubled to 50,000 units due to the strong demand anticipated by Marionnaud's management. The first order, on track to be delivered during the second quarter of 2024, will generate around GBP2 million in revenue for Incanthera, ImmuPharma said. ImmunPharma holds an 11% stake in Incanthera. ImmuPharma Chief Operating Officer Tim Franklin comments: "As a major shareholder in Incanthera, we are delighted with this further progress and in particular Incanthera's revenue momentum and move into profitability. This highlights the strong financial asset we have in Incanthera and the enormous opportunities within the company's revolutionary skincare range and its partnership with Marionnaud."

----------

Caspian Sunrise PLC, up 26% at 3.28p, 12-month range 2.20p-7.49p. The Kazakhstan-focused oil and gas exploration and production company said it was mulling the sale of all or part of the BNG contract area's shallow structures at "indicative prices potentially significantly greater than its current carrying value". Says any deal would likely require shareholder approval due to its size of the transaction value relative to the group. "We believe this heightened level of corporate interest in BNG's producing shallow structures is in part the result of the changes last year to the Kazakh oil trading regulations, which now require the production of oil to obtain a trading licence, and the relative scarcity of producing fields with full production licences. The sharp reduction in the discount for international sales referred to below may also have had an effect," the company says. Caspian Sunrise says no binding agreements have been entered into and there is no certainty that discussions will lead to a firm offer or that the board would put an offer before shareholders.

----------

AIM - LOSERS

----------

Aeorema Communications PLC, down 19% at 60.5p, 12-month range 55.00p-119.40p. In the six months that ended December 31, swings to pretax loss of GBP243,534 from a profit of GBP326,021 a year earlier. Revenue falls to GBP6.6 million from GBP7.1 million, while administrative expenses rise to GBP1.7 million from GBP1.2 million. Expects full-year revenue of no less than GBP19 million compared to GBP20.2 million in the financial year that ended June 30, 2023. Chair Mike Hale comments: "With a focus on adaptability and forward planning, Aeorema is well positioned for the future and is confident in its ability to deliver sustainable growth and value creation over the long term. We also expect to reaffirm our commitment to shareholders by maintaining our dividend policy. While this half year's financial performance reflects the impact of project timing, we are encouraged by the underlying strength of our business and our pipeline. Our focus remains steadfast on delivering creative brilliance for our clients on a global scale, and sustained growth and value to our shareholders."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
16 Jul 2021 11:19

AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks

AIM WINNERS & LOSERS: Pantheon up on resource upgrade, farmout talks

Read more
24 Jun 2021 13:40

IN BRIEF: Immupharma moves step closer to Lupazor phase three trial

IN BRIEF: Immupharma moves step closer to Lupazor phase three trial

Read more
21 Jun 2021 16:11

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
24 May 2021 15:32

EXECUTIVE CHANGES: Gresham House Strategic plots future as chair exits

EXECUTIVE CHANGES: Gresham House Strategic plots future as chair exits

Read more
29 Apr 2021 17:33

TRADING UPDATES: Keystone Law and Checkit post annual revenue growth

TRADING UPDATES: Keystone Law and Checkit post annual revenue growth

Read more
9 Feb 2021 14:13

ImmuPharma clarifies next steps for phase 3 Lupuzor trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on the new optimised international phase 3 trial of 'Lupuzor' in the potentially life-threatening auto-immune disease systemic lupus erythematosus (SLE) on Tuesday.

Read more
9 Feb 2021 10:42

AIM WINNERS & LOSERS: Tavistock Rises As Tips Annual Earnings Climb

AIM WINNERS & LOSERS: Tavistock Rises As Tips Annual Earnings Climb

Read more
9 Feb 2021 10:36

No Conditional US Approval So Far For ImmuPharma Lupus Drug Lupuzor

No Conditional US Approval So Far For ImmuPharma Lupus Drug Lupuzor

Read more
24 Nov 2020 21:30

UK TRADING UPDATE SUMMARY: Gore Street Energy Energises Drumkee

UK TRADING UPDATE SUMMARY: Gore Street Energy Energises Drumkee

Read more
23 Nov 2020 14:29

IN BRIEF: Immupharma Says L1 Capital Converts USD200,000 Of Security

IN BRIEF: Immupharma Says L1 Capital Converts USD200,000 Of Security

Read more
20 Nov 2020 12:15

ImmuPharma gets December date for FDA meeting

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on the new optimised international phase 3 trial of 'Lupuzor' in systemic lupus erythematosus (SLE) on Friday, reporting that the US Food & Drug Administration (FDA) has now confirmed the date of 4 December for a Type 'A' Meeting Request.

Read more
20 Nov 2020 11:04

ImmuPharma Partner To Discuss Progression Of Lupuzor Drug With US FDA

ImmuPharma Partner To Discuss Progression Of Lupuzor Drug With US FDA

Read more
10 Nov 2020 17:40

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

Read more
30 Sep 2020 18:37

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

Read more
29 Sep 2020 18:19

IN BRIEF: Immupharma Raises Stake In Incanthera To 15.4%

IN BRIEF: Immupharma Raises Stake In Incanthera To 15.4%

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.